Colliers International

Miss Kaleigh Haeg
Head of Life Sciences (UK/EMEA) 

Cresset Discovery Services

Dr David Bardsley
Commercial Director 

Crystec Pharma

Crystec applies the latest mSAS (modified supercritical anti-solvent) technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries, contributing to human health by enabling new and more effective therapies. Crystec SCF technologies can be applied to small and large drug molecules in a range of dosage forms. Our services include crystal form screening and particle design (including composite particles and co-crystals), addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management. Our process is scaled to GMP manufacturing levels. We are also engaged in in-house programmes to develop improved products and currently have licensing opportunities available in several therapeutic areas, including urge incontinence, fungal infections, and malaria. The first product based on SCF technology is expected to launch this year. It is an inhaled product for migraine - SCF processing enables exceptional particle size control and lung deposition resulting in rapid uptake. The particle design and scale-up to GMP for this product were managed by members of the Crystec team. Follow us on LinkedIn and Twitter

Miss Catherine Hunter
Business Development Director 
Mr Paul Thorning
CEO 

East Midlands Business (Midlands Engine)

Mrs Louise Stock
Healthcare & Biotechnology Sector Specialist - Department for International Trade East Midlands 

EUSA Pharma

EUSA Pharma has a portfolio of five approved as well as several named-patient specialty hospital products, including: Caphosol®, Xenazine®, Collatamp®, Custodiol® and Fomepizole® EUSA submitted the MAA for FOTIVDA (tivozanib HCL) as first line therapy for RCC in Q1 of 2016. EUSA Pharma has ambitious plans to expand its portfolio through acquisition and in-licensing and is led by an experienced management team with a strong record of building successful specialty pharmaceutical companies. The EUSA Pharma business is supported by significant funding raised from leading life science investor Essex Woodlands. In addition to direct commercial operations across the EU and US, EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America and makes products available in approximately 40 countries across the world through this broad international platform.

Mr Lee Morley
CEO 
Dr Benjamin Owens
Head of Business Development 

Genetic Microdevices

Dr Dimitrios Sideris
CEO 

Image Analysis Group

Dr Olga Kubassova
CEO 

InoCardia

Dr Jeremy Billson
CEO 

Iontas

IONTAS is a biotechnology company formed in Cambridge, UK, in 2014 in order to advance the development of novel antibody therapeutics. Established on research of the founder, John McCafferty, it employs proprietary technologies and services in all key areas of therapeutic antibody discovery and development. The company applies expertise in antibody engineering and assay development to ensure projects are delivered within specification and timeframe. Our services are tailored to the specific requirements of each Partner, which facilitates delivery of project objectives in a timely manner. Further to the services offered by IONTAS, we are seeking to partner with select companies to develop new antibody based therapies in the areas of cancer and inflammation.
Website:
www.iontas.co.uk
Dr John McCafferty
CEO 
Dr Neil Butt
CBO 

Ipsen

Dr Siau Bai
Director Corporate Business Development 
Dr Olivier Crauk
Director Corporate Business Development